Trial reportNature medicine2021
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
Open access · hybridAbstract readClinical Trial, Phase IMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
8.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Broadly neutralizing antibodies for HIV therapy in clinical trials: a systematic review.Infectious diseases of poverty · 2026Pooled it
- Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States.PLoS pathogens · 2023Pooled it
- Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.Nature medicine · 2026Trial
- VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.The Journal of infectious diseases · 2025Trial
- Hyaluronidase-enhanced subcutaneous delivery of bNAbs: a phase 1 randomized controlled clinical trial in HIV-uninfected women.Nature communications · 2025Trial
- Trial
- Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.Nature medicine · 2024Trial
- Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.PLoS medicine · 2024Trial
- Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.Nature medicine · 2022Trial
- Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.The Journal of infectious diseases · 2022Trial
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.Nature medicine · 2022Trial
- Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies.Science advances · 2026Article
- Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.Gene therapy · 2026Article
- Miniaturized subcutaneous cellular implants for sustained therapeutic protein delivery in resource-limited settings.bioRxiv : the preprint server for biology · 2026Article
- Diverse paths to broadly neutralizing antibody escape among HIV-1 strains.Nature microbiology · 2026Article
- Review
- Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.Communications medicine · 2026Review
- Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Human immunodeficiency virus vaccines: Advances, challenges and future perspectives.World journal of virology · 2026Review
- Predicting viral sensitivity to antibodies using genetic sequences and antibody similarities.PLoS computational biology · 2026Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 8 institutions in 1 country.
Kathryn E Stephenson *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Boris Julg *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
C Sabrina TanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Rebecca ZashCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Stephen R WalshCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0817-9370
Charlotte-Paige RolleOrlando Immunology Center, Orlando, FL, USA.
Ana N MonczorMcGovern Medical School at The University of Texas Health Science Center, Houston, TX, USA.
Sofia LupoMcGovern Medical School at The University of Texas Health Science Center, Houston, TX, USA.
Huub C GelderblomInternational AIDS Vaccine Initiative, New York, NY, USA.ORCID http://orcid.org/0000-0003-4786-1003
Jessica L AnselCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Diane G KanjilalCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Lori F MaxfieldCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7595-6205
Joseph NkololaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Erica N BorducchiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Peter AbbinkCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1978-088X
Jinyan LiuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Lauren PeterCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2105-7503
Abishek ChandrashekarCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7821-5552
Ramya NityanandamCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Zijin LinCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Alessandra SetaroCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Joseph SapienteCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Zhilin ChenRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Lisa SunnerInternational AIDS Vaccine Initiative, New York, NY, USA.
Tyler CassidyTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0003-0757-0017
Chelsey BennettStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Alicia SatoStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Bryan MayerStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2258-5276
Alan S PerelsonTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0002-2455-0002
Allan deCampStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Frances H PriddyInternational AIDS Vaccine Initiative, New York, NY, USA.
Kshitij WaghTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
Elena E GiorgiTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
Nicole L YatesDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Roberto C ArduinoMcGovern Medical School at The University of Texas Health Science Center, Houston, TX, USA.
Edwin DeJesusOrlando Immunology Center, Orlando, FL, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Bette KorberTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA. dbarouch@bidmc.harvard.edu.ORCID http://orcid.org/0000-0001-5127-4659
Beth Israel Deaconess Medical Center · USLos Alamos National Laboratory · USFred Hutch Cancer Center · USInternational AIDS Vaccine Initiative · USThe University of Texas Health Science Center at Houston · USDuke University · USOrlando Immunology Center · USRagon Institute of MGH, MIT and Harvard · US
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MConsortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0MCombined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6MProject 2U19AI128751 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2018 to 2022
$14.0MAd26 Based Therapeutic Vaccines for HIVU01AI145801 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., JUELG, BORIS DOMINIK · 2020 to 2025
$9.0MViral dynamics of rebound and control following early treatment of HIV/SIVP01AI131365 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2017 to 2021
$7.5MModeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0MSingle-Cell Analysis of the HIV/SIV ReservoirR01AI149670 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., SHALEK, ALEX K · 2020 to 2024
$4.6MImpact of the Intestinal Microbiome on HIV/SIV VaccinesR01OD024917 · OD · WASHINGTON UNIVERSITY · PI BALDRIDGE, MEGAN T, BAROUCH, DAN H. · 2017 to 2021
$4.3MImmune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7MOptimization of Broadly Neutralizing Antibodies for HIV EradicationR01AI129797 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2017 to 2021
$3.6MImmune System Modeling/HIVR37AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 2002 to 2011
$2.4MNCATS NIH HHS UL1 TR001102NIAID NIH HHS K08 AI106408NIAID NIH HHS K23 AI114381NIAID NIH HHS P01 AI131365NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI129797NIAID NIH HHS R01 AI149670NIAID NIH HHS R37 AI028433NIAID NIH HHS U01 AI145801NIAID NIH HHS U19 AI128751NIAID NIH HHS UM1 AI124377NIAID NIH HHS UM1 AI126603NIH HHS R01 OD011095NIH HHS R01 OD024917
Abstract
Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-glycan-specific antibody PGT121 at 3, 10 and 30 mg kg
Indexed as
AdultAntiretroviral Therapy, Highly ActiveAntiviral AgentsBroadly Neutralizing AntibodiesCD4-Positive T-LymphocytesDouble-Blind MethodFemaleHIV-1HIV Envelope Protein gp120HIV InfectionsHumansMaleMiddle AgedPeptide FragmentsPlacebosViral LoadAntiviral AgentsBroadly Neutralizing AntibodiesHIV Envelope Protein gp120HIV envelope protein gp120 (305-321)Peptide FragmentsPlacebos
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.